Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether low-molecular-weight heparin could be equally or more effective than oral anticoagulation in the long-term treatment of deep venous thrombosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitari de Bellvitge
• Collaborator: LEO Pharma
• Treatments: Acenocoumarol; Anticoagulants; Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin; Vitamin K; Vitamins

Criteria

Inclusion Criteria:

• Consecutive, symptomatic patients with a first or recurrent episode of acute proximal-vein thrombosis of the lower limbs.

• either sex and over 18 years of age

• referred to the Vascular Surgery Department of the hospital

• onset of symptoms less than 2 weeks

• documented by compression ultrasonography,

Exclusion Criteria:

• received heparin, low-molecular-weight heparin or oral anticoagulant therapy for more than 2 days for the present disease

• pulmonary embolism requiring thrombolytic therapy

• Need of surgical thrombectomy or vena cava interruption

• receiving oral anticoagulant treatment or antiplatelet agents for other conditions

• contraindication to anticoagulant treatment (active bleeding, severe blood pressure or allergy to the study drugs)

• platelet count lower than 100x103 /μl or hemoglobin concentration lower than 7 g/dl or history of heparin-associated thrombocytopenia

• severe renal failure necessitating dialysis

• pregnancy

• lumbar puncture within the previous 24 hours